Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs (Q29626)

From lgbtDB
Jump to navigation Jump to search
No description defined
  • Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs.
  • Testosterone-induced erythrocytosis in transgender males
Language Label Description Also known as
English
Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs
No description defined
  • Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs.
  • Testosterone-induced erythrocytosis in transgender males

Statements

title
Testosterone-induced erythrocytosis in transgender males: Challenges arising from an increasing prevalence of metabolic syndrome and wider therapeutic indications for prescribing SGLT2 inhibitor drugs. (English)
1 reference
stated in
PubMed
date published
September 2024
1 reference
stated in
PubMed
date issued
September 2024
1 reference
stated in
PubMed
volume
38
1 reference
stated in
PubMed
issue
5
1 reference
stated in
PubMed
page(s)
101930
1 reference
stated in
PubMed
page start
101930
1 reference
stated in
PubMed
publisher item identifier
S1521-690X(24)00105-2
1 reference
stated in
PubMed
 
Retrieved from "https://lgbtdb.wikibase.cloud/w/index.php?title=Item:Q29626&oldid=181373"